{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:10:31Z","timestamp":1782778231956,"version":"3.54.5"},"reference-count":57,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Ulcerative colitis is a chronic immune\u2010mediated inflammatory disease of the colon that causes considerable morbidity and increases the risk of colorectal cancer. Several targeted therapies have been developed for moderate\u2010to\u2010severe ulcerative colitis, significantly improving its management. Ozanimod and etrasimod, oral small\u2010molecule drugs, are the latest addition. They belong to the class of sphingosine\u20101\u2010phosphate receptor (S1PR) modulators and are the first members of this class to be granted approval for ulcerative colitis. They act by blocking lymphocyte trafficking from lymph nodes to inflamed tissues without impairing other immune system functions. This narrative review summarizes current knowledge of sphingosine\u20101\u2010phosphate receptor modulators, focusing on safety. Safety data from the field of multiple sclerosis (MS) will be discussed because the first S1PR modulator to reach the market, fingolimod, was used extensively for relapsing\u2010remitting MS. Indications for the safe use of ozanimod and etrasimod in ulcerative colitis patients will be provided.<\/jats:p>","DOI":"10.1002\/ueg2.70026","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T02:39:23Z","timestamp":1749436763000},"page":"1077-1091","source":"Crossref","is-referenced-by-count":6,"title":["Sphingosine\u20101\u2010Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2870-3827","authenticated-orcid":false,"given":"Massimo C.","family":"Fantini","sequence":"first","affiliation":[{"name":"Department of Medical Science and Public Health University of Cagliari  Cagliari Italy"},{"name":"Azienda Ospedaliero\u2010Universitaria di Cagliari  Cagliari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine University of Rome Tor Vergata  Rome Italy"},{"name":"Unit of Neurology IRCCS Neuromed  Pozzilli Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giacobazzi","sequence":"additional","affiliation":[{"name":"Medical Affairs Pfizer Italy  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Benemei","sequence":"additional","affiliation":[{"name":"Medical Affairs Pfizer Italy  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Romeo","sequence":"additional","affiliation":[{"name":"Cardiology Unit University of Campania \u201cLuigi Vanvitelli\u201d  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.08.039"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)00966\u20102"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231218615"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020641"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab178"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102021\u2010326390"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.094805"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010021\u201000574\u20107"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2178898"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.007"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00244\u20100"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16741"},{"key":"e_1_2_10_17_1","unstructured":"\u201cEuropean Medicines Agency Summary of Product Characteristics \u2013 Zeposia (Ozanimod) \u201d accessed December 10 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeposia."},{"key":"e_1_2_10_18_1","unstructured":"\u201cEuropean Medicines Agency Summary of Product Characteristics \u2013 Velsipity (Etrasimod) \u201d accessed December 10 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/velsipity."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155014"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S43453"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.09.003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2297"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100814\u20101"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(14)70049\u20103"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800149"},{"key":"e_1_2_10_28_1","unstructured":"\u201cEuropean Medicines Agency Summary of Product Characteristics \u2013 Mayzent (Siponimod) \u201d accessed December 10 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent."},{"key":"e_1_2_10_29_1","unstructured":"\u201cEuropean Medicines Agency Summary of Product Characteristics \u2013 Ponvory (Ponesimod) \u201d accessed December 10 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ponvory."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52017"},{"key":"e_1_2_10_31_1","unstructured":"\u201cEuropean Medicines Agency Summary of Product Characteristics \u2013 Gilenya (Fingolimod) \u201d accessed December 10 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gilenya."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt\u20102022\u20100255"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001528\u20108"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513248"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)00061\u20102"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjae038"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab012"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjad146"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco\u2010jcc\/jjab016"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010023\u201008178\u20108"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.06.028"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2014.11.012"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221133163"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.05.005"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.06.006"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419878324"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer\u20102019\u20100169"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.383"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1376494"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221102584"},{"key":"e_1_2_10_53_1","unstructured":"\u201cReproductive Toxicity \u201d accessed January 23 2025 https:\/\/www.fingolimodinfo.com\/en\/reproductive\u2010toxicity."},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231216854"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.018"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1379"},{"key":"e_1_2_10_57_1","first-page":"10","article-title":"Etrasimod for the Treatment of Ulcerative Colitis: Up to 2.5 Years of Pooled Safety Data From Global Clinical Trials","volume":"19","author":"Vermiere S.","year":"2023","journal-title":"Gastroenterology and Hepatology"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1388"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:56:14Z","timestamp":1761137774000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/ueg2.70026"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.70026","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]}}}